A total of 29% vs. 21% of patients with PD-L1 expression on ≥1% of tumor cells were alive after 4 years of observation in the group treated with the combination treatment and in the group receiving nivolumab monotherapy, respectively. This evidence concerns the gene CD274 and neoplasm.